Skip to content Skip to footer
Subscribe Now

INSIGHTS+

PharmaShots' Key Highlights of Fourth Quarter 2020
PharmaShots’ Key Highlights of Fourth Quarter 2020
The fourth quarter of 2020 contains multiple initiations of clinical trials, big approvals, and numerous deals. COVID-19 related news remains at the peak in this quarter Multiple companies received regulatory bodies EUA for their vaccines and treatments for COVID-19. Initiating with, Regeneron sought the US FDA's EUA for REGN-COV2 Ab combination while Health Canada accelerated…
January 14, 2021
PharmaShots' Most Read News of 2020
PharmaShots’ Most Read News of 2020
Lockdown' declared Collins Dictionary word of the year. The year 2020, well known as COVID-19 year has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements, and gaining approvals. Our team has compiled a list of 30 most read life sciences news on PharmaShots in 2020. 1. Bayer…
January 6, 2021
Insights+: The US FDA New Drug Approvals in November 2020
Insights+: The US FDA New Drug Approvals in November 2020
The US FDA has approved 5 NDAs and 1 BLA in Nov 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 96 novel products so far in 2020, including 6 in Nov 2020.…
December 17, 2020
Insights+ Key Biosimilars Events of November 2020
Insights+ Key Biosimilars Events of November 2020
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a 'reference…
December 3, 2020
Insight+_Senior Editor
Insights+: The US FDA New Drug Approvals in October 2020
The US FDA has approved 4 NDAs and 1 BLA in Oct 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 90 novel products so far in 2020, including 5 in Oct 2020.…
November 19, 2020
Insight+_Senior Editor
Insights+ Key Biosimilars Events of October 2020
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency During the month of October, Henlius signed two agreements for its biosimilar products and presented results of HLX03 (biosimilar, adalimumab) whereas Samsung Bioepis and Biogen announced EMA filing acceptance of SB11 (biosimilar, ranibizumab) Our team at PharmaShots…
November 5, 2020
Load more